Table 3.
Pathogens identified and antibiotic therapies used in 344 hospitalizations among 216 IVDU*
| n (%) | |
| Pathogens | |
| Staphylococcus aureus | 131‡ (38.1) |
| Beta-hemolytic streptococci | 42 (12.2) |
| Viridans streptococci | 30 (8.7) |
| Enterobacteriaceae | 17 (4.9) |
| Streptococcus pneumoniae | 14 (4.1) |
| Pseudomonas aeruginosa | 10 (2.9) |
| Coagulase-negative staphylococci | 6 (1.7) |
| Mycobacteria spp. | 6 (1.7) |
| Other pathogens | 15 (4.4) |
| Polymicrobial infections | 64 (18.6) |
| No pathogen identified | 73 (21.2) |
| Therapy† | |
| Beta-lactams | 292 (84.9) |
| Amoxicilline/Clavulanate | 129 (37.5) |
| Penicilline | 54 (15.7) |
| Flucloxacilline | 48 (14.0) |
| Cephalosporines | 33 (9.6) |
| Piperacilline/Tazobactam | 18 (5.2) |
| Carbapenemes | 10 (2.9) |
| Non-beta-lactams | |
| Aminoglycosides (used in combination) | 10 (2.9) |
| Fluoroquinolones | 8 (2.3) |
| Antituberculosis drugs | 6 (1.7) |
| Others | 28 (8.1) |
* seen by an ID during a period of 5 years.
† Antibiotic prescribed for the longest period intravenously during one hospitalization.
‡ Two of 131 (1.53%) S.aureus infections were due to methicillin-resistant S.aureus (MRSA).